Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 93-102

  Lee, Martin L ^a   Gale, Robert Peter ^b   Yap, Peng Lee ^c  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b Salick Health Care Inc   (United States)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Clinical use; Efficacy; Immune deficiency; Intravenous immunoglobulin; Safety

Indexed keywords

IMMUNOGLOBULIN;

HUMAN; IMMUNE DEFICIENCY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL TRIALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, INTRAVENOUS; OPPORTUNISTIC INFECTIONS; TREATMENT OUTCOME;

EID: 0031047539     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.93     Document Type: Review

References (112)

1. Webster ADB, Lever AML. 1986. Intramuscular versus intravenous administration of immunoglobulin preparations. In Clinical Use of Intravenous Immunoglobulins, ed. A Morell, UE Nydegger, pp. 67-75. London: Academic
2. Ochs HD, Lee ML, Fischer SH. 1987. Efficacy of a new intact intravenous immunoglobulin preparation (Gammagard®) in primary immunodeficient patients. Clin. Ther. 9:512-22
3. Berkman SA, Lee ML, Gale RP. 1987. Clinical uses of intravenous immunoglobulins. Ann. Int. Med. 112:278-92
4. Apfelzweig R, Piszkiewicz D, Hooper JA. 1987. Immunoglobulin A concentrations in commercial immune globulins. J. Clin. Immunol. 7:46-50
5. Cottier H, Hassig A. 1986. Immunodeficiency and ineffective immune responses. In Clinical Use of Intravenous Immunoglobulins, ed. A Morell, UE Nydegger, pp. 1-13. London: Academic
6. Roifman CM, Rao CP, Lederman HM, et al. 1986. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am. J. Med. 80:590-94
7. Ochs HD, Ament ME, Davis SD. 1972. Giardiasis with malabsorption in X-linked agammaglobulinemia. N. Engl. J. Med. 287:341-42
8. Saulsbury FT, Winkelstein JA, Yolken RH. 1980. Chronic rotavirus infection in immunodeficiency. J. Pediatr. 97:61-65
9. Buckley RH. 1982. Long term use of intravenous immune globulin in patients with primary immunodeficiency disease: inadequacy of current dosage practices and approaches to the problem. J. Clin. Immunol. 2:15-21S
10. Ochs HD, Fischer SH, Wedgwood RJ. 1982. Modified immune globulin: its use in the prophylactic treatment of patients with immune deficiency. J. Clin. Immunol. 2: 22-30S
11. Nolte MT, Pirofsky B, Gerritz GA, Golding B. 1979. Intravenous immunoglobulin therapy for antibody deficiency. Clin. Exp. Immunol. 36:237-43
12. Ochs HD, Morell A, Skvail F, et al. 1986. Survival of IgG subclasses following administration of intravenous gammaglobulin in patients with primary immunodeficiency diseases. In Clinical Use of Intravenous Immunoglobulins, ed. A Morell, UE Nydegger, pp. 77-85. London: Academic
13. Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. 1984. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann. Intern. Med. 101:435-39
14. Pirofsky B, Anderson CJ, Bardana EJ. 1980. Therapeutic and detrimental effects of intravenous immunoglobulin therapy. In Immunoglobulins: Characteristics and Uses of Intravenous Preparations, ed. BM Alving, JS Finlayson, pp. 15-22. Washington, DC: Dept Health & Hum Serv
15. Bernatowska E, Madalinski K, Janowicz W, et al. 1987. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin. Immunol. Immunopathol. 43:153-62
16. Pirofsky B. 1984. Intravenous immune globulin therapy in hypogammaglobulinemia. A review. Am. J. Med. 76:53-60
17. Pirofsky B, Campbell SM, Montanaro A. 1982. Individual patient variations in the kinetics of intravenous immune globulin administration. J. Clin. Immunol. 2:7-148
18. Ochs HD, Lee ML, Fischer SH, et al. 1987. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home. J. Infect. Dis. 156:652-54
19. Leen CL, Yap PL, McClelland DB. 1986. Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinemia by dosage individualization of intravenous immunoglobulin. Vox Sang. 51:278-86
20. Hauser GJ, Spirer Z. 1986. Point: gamma globulin therapy for children with recurrent respiratory infections. Pediatr. Infect. Dis. 5:393-94
21. Berger M. 1987. Immunoglobulin G subclass determination in diagnosis and management of antibody deficiency syndromes. J. Pediatr. 110:325-28
22. Oxelius VA. 1974. Chronic infections in a family with hereditary deficiency of IgG2 and IgG4. Clin. Exp. Immunol. 17:19-27
23. Oxelius VA, Laurell AB, Lindquist B, et al. 1981. IgG subclasses in selective IgA deficiency. N. Engl. J. Med. 304:1476-77
24. Hill HR. 1986. Counterpoint: gamma globulin therapy for children with recurrent respiratory infections. Again! Why not? Pediatr. Infect. Dis. 5:395-98
25. Smith TF, Tiller TL, Muldoon M, Pandey J. 1987. Use of intravenous immunoglobulin (IVIG) in children with chronic chest symptoms. Presented at Am. Acad. Allergy Immunol., Las Vegas (Abstr. 16)
26. Page R, Friday G, Stillwagon P, et al. 1987. Improvement of asthma in IgG subclass deficient asthmatics following IgG replacement therapy. Presented at Am. Acad. Allergy Immunol., Las Vegas (Abstr. 253)
27. Silk H, Geha RS. 1987. Intravenous gammaglobulin (IVGG) prophylaxis in children with IgG2 deficiency. Presented at Am. Acad. Allergy Immunol., Las Vegas (Abstract 254)
28. Shackelford PG, Granoff DM, Polmar SH, et al. 1990. Subnormal serum concentrates of IgG2 in children with frequent infections associated with varied patterns of immunologic dysfunction. J. Pediatr. 116: 529-38
29. Mankarious S, Lee M, Fischer S, et al. 1988. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J. Lab. Clin. Med. 112:634-40
30. Ballow M, Cates KL, Rowe JC, et al. 1986. Development of the immune system in very low birth weight (less than 1500g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr. Res. 20:899-904
31. Wilkinson HW. 1978. Group B streptococcal infections in humans. Annu. Rev. Microbiol. 32:41-57
32. Anthony BF, Okada DM. 1977. The emergence of group B streptococci in infections of the newborn infant. Annu. Rev. Med. 28:355-69
33. Baker CJ. 1977. Summary of the workshop on perinatal infections due to group B Streptococcus. J. Infect. Dis. 136:137-52
34. Haque KN, Zaidi MH, Haque SK, et al. 1986. Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants. Pediatr. Infect. Dis. 5:622-25
35. Chirico G, Rondini G, Plebani A, et al. 1988. Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates. J. Pediatr. 110:437-42
36. Stabile A, Miceli Sopa S, Romanelli V, et al. 1988. Intravenous immunoglobulin for prophylaxis of neonatal sepsis in premature infants. Arch. Dis. Child. 63:441-43
37. Conway SP, Ng PC, Howel D, et al. 1990. Prophylactic intravenous immunoglobulin in pre-term infants: a controlled trial. Vox. Sang. 59:6-11
38. Clapp DW, Kliegman RM, Baley JE, et al. 1989. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants. J. Pediatr. 115:973-78
39. Magny JF, Bremard-Oury C, Brault D, et al. 1991. Intravenous immunoglobulin therapy for prevention of infection in high-risk premature infants: report of a multicenter, double-blind study. Pediatrics 88: 437-43
40. Kinney J, Mundorf L, Gleason C, et al. 1991. Efficacy and pharmacokinetics of intravenous immune globulin administration to high-risk neonates. Am. J. Dis. Child. 145:1233-38
41. Baker CJ, Melish ME, Hall RT, et al. 1992. Intravenous immune globulin for the prevention of nosocomial infection in low-birth weight neonates. N. Engl. J. Med. 327:213-19
42. Fanaroff AA, Korones SB, Wright LL, et al. 1994. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N. Engl. J. Med. 330:1107-13
43. NIH Consensus Conference. 1990. Intravenous immunoglobulin: prevention and treatment of disease. JAMA 264:3189-93
44. Munster AM. 1986. Infections in burns. In Clinical Use of Intravenous Immunoglobulins, ed. A Morell, UE Nydegger, pp. 339-44. London: Academic
45. Pruitt BA Jr, McManus AT. 1984. Opportunistic infections in severely burned patients. Am. J. Med. 76:146-54
46. Pollack M. 1983. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J. Infect. Dis. 147:1090-98
47. Munster AM, Moran KT, Thupari J, et al. 1987. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. J. Burn Care Rehabil. 8:376-80
48. Hunt JL, Purdue GF. 1987. A clinical trial of tetravalent hyperimmune pseudomonas-IV immunoglobulin G in burn patients with pseudomonas sepsis. Proc. Am. Burn Assoc. Annu. Meet., Washington, DC (Abstr. 161)
49. Duswald KH, Muller K, Seifert J, et al. 1980. Gammaglobulin gegen bakterielle Infectionen chirurgischer Patienten Ergbnisse einer kontrollierten, randomisierten klinischen Studie. Muench. Med. Wochenschr. 122:832-35
50. Glinz W, Grob PJ, Nydegger UE, et al. 1985. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med. 11:288-94
51. Just HM, Vogel W, Metzger M, et al. 1986. Treatment of intensive care unit patients with severe nosocomial infections. In Clinical Use of Intravenous Immunoglobulins, ed. A Morell, UE Nydegger, pp. 345-52. London: Academic
52. The Intravenous Immunoglobulin Collaborative Study Group. 1992. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N. Engl. J. Med. 327:234-40
53. Ziegler EJ, McCutchan JA, Fierer J, et al. 1992. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1225-30
54. Duswald KH, Müller K, Seifert J, et al. 1980. Wirksamkeit von i.e. Gammaglobulin gegen backterielle infektionen chirurgischer Patienten. Muench. Med Wochenschr. 122:832-36
55. Glinz W, Grob JP, Nydegger UE, et al. 1985. Polyvalent immunoglobulins for prophylaxis of infections in patients with multiple trauma. Bact. Intensive Care Med. 11: 288-94
56. McCutchan JA, Wolf JL, Ziegler EJ, et al. 1983. Ineffectiveness of single dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infection in patients with prolonged neutropenia. Schweiz. Med. Wochenschr. 113(Suppl. 14):40-45
57. Baumgartner JD, Glauser MP, McCutchan JA, et al. 1985. Prevention of gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet 2:59-63
58. Kapadia SB. 1980. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine 59: 380-92
59. Twomey J. 1973. Infections complicating multiple myeloma and chronic lymphocytic leukaemia. Arch. Inter. Med. 132: 562-65
60. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukaemia. 1988. IVIg for the prevention of infection in chronic lymphocytic leukaemia. N. Engl. J. Med. 319:902-7
61. Chapel HM, Lee M, Hargreaves R, et al. 1994. Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 343:1059-63
62. Griffiths H, Lea J, Bunch C, et al. 1992. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin. Exp. Immunol. 89:374-77
63. Hargreaves RM, Lea JR, Griffiths H, et al. 1995. Immunological factors and risk of infection in plateau phase myeloma. J. Clin. Pathol. 48:260-66
64. Chapel H, Dicato M, Gamm H, et al. 1994. Immunoglobulin replacement in patients with chronic lymphocytic leukemia: a comparison of two dose regimens. Br. J. Haematol. 88:209-12
65. Besa EC. 1984. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am. J. Hematol. 76:209-18
66. Shedel I. 1986. Application of immunoglobulin preparations in multiple myeloma. In Clinical Use of Intravenous Immunoglobulins, ed. A Morell, UE Nydegger, pp. 123-32. London: Academic
67. Weeks JC, Tierney MR, Weinstein MC. 1991. Cost effectiveness of prophylactic intravenous immunoglobulin in chronic lymphocytic leukemia. N. Engl. J. Med. 325:81-86
68. Lee ML, Courter SG. 1994. Quality of life assessment versus clinical outcome measures: an example. Drug Inform. J. 28: 39-43
69. Winston DJ, Pollard RB, Ho WG, et al. 1982. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann. Intern. Med. 97:11-18
70. Meyers JD, Leszczynski J, Zaia JA, et al. 1983. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann. Intern. Med. 98:442-46
71. Bowden RA, Sayers M, Flournoy N, et al. 1986. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl. J. Med. 314:1006-10
72. Winston DJ, Ho WG, Lin TH, et al. 1987. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 106:12-18
73. Kubanek B, Ernst P, Ostendorff P, et al. 1985. Preliminary data of controlled trial of hyperimmune globulin in the prevention of cytomegalovirus in bone marrow transplant recipients. Transplant. Proc. 117: 468-69
74. Wolff SN, Fay JW, Herzig RH, et al. 1993. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantations or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann. Intern. Med. 11:937-42
75. Nicholls AJ, Brown CB, Edward N, et al. 1983. Hyperimmune immunoglobulin for cytomegalovirus infections. Lancet 1: 532-33
76. Blacklock HA, Griffiths P, Stirk P, Prentice HG. 1985. Specific hyperimmune globulin for cytomegalovirus pneumonitis. Lancet 2:152-53 (Lett.)
77. Reed EC, Bowden RA, Dandliker PS, Meyers JD. 1986. Efficacy of cytomegalovirus immune globulin in marrow transplant patients with cytomegalovirus pneumonia. In Progr. Abstr. 26th Intersci. Conf. Antimicrob. Agents Chemother., p. 231. Washington, DC: Am. Soc. Microbiol. (Abstr. 731)
78. Emanuel D, Cunningham I, Jules-Elysee K, et al. 1988. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109:777-82
79. Reed EC, Bowden RA, Dandliker PS, et al. 1988. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109:783-88
80. Snydman DR, Werner BG, Heinze-Lacey B, et al. 1987. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317:1049-54
81. Graneto D, Swift C, Steinmuller DR, et al. 1988. Use of intravenous immunoglobulin (Ig) prophylaxis for primary cytomegalovirus (CMV) infection post living-related donor (LRD) renal transplantation. In Abstr. Am. Soc.Transplant Physicians Annu. Meet., Chicago (Abstr. 10)
82. Light JA, Khawand N, Brems W, et al. 1988. Does IVIG prevent primary CMV disease in kidney transplant recipients? In Abstr. Am. Soc. Transplant Physicians Annu. Meet., Chicago (Abstr. 11)
83. Wreghitt T. 1989. Cytomegalovirus infections in heart and heart-lung transplant recipients. J. Antimicrob. Chemother. 23: 49-60
84. Schaefers HJ, Milbradt H, Flik J, et al. 1988. Hyperimmunoglobulin for cytomegalovirus prophylaxis following heart transplantation. Clin. Transplant. 2:51-56
85. Loebe M, Schueler S, Warnecke H, et al. 1987. Infection after heart transplantation. Cardiothorac. Surg. 38:7-12
86. Balk AHMM, Welmar W, Rothbarth PH, et al. 1983. Passive immunization against cytomegalovirus in allograft recipients: Rotterdam. Heart transplant program experience. Infection 21:195-200
87. Havel M, Teufelsbachter H, Laczkovics A, et al. 1990. Cytomegalovirus hyperimmunoglobulin prophylaxis of cytomegalovirus infection in immunosuppressed heart transplant recipients. Transplant. Proc. 22: 1805-6
88. Laske A, Gallino A, Carrel T, et al. 1993. Cytomegalovirus infection and prophylaxis in heart transplantation. Transplant. Proc. 25:1427-28
89. Silverman BA, Rubinstein A. 1985. Serum lactate dehydrogenase levels in adults and children with acquired immune deficiency syndrome (AIDS) and AIDS-related complex: possible indicator of lymphoproliferation and disease activity. Effect of intravenous gammaglobulin on enzyme levels. Am. J. Med. 78:728-36
90. Calvelli TA, Rubinstein A. 1986. Intravenous gamma-globulin in the acquired immunodeficiency syndrome. Pediatr. Infect. Dis. 5:5207-10
91. Gupta A, Novick BE, Rubinstein A. 1986. Restoration of suppressor cell functions in children with AIDS following intravenous gammaglobulin treatment. Am. J. Dis. Child. 140:143-46
92. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. 1991. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N. Engl. J. Med. 325:73-80
93. Bruckmann C, Auberger K, Neumann K, et al. 1988. Continuous IV immunoglobulin-substitution in HIV-positive haemophilic patients. In Abstr. Meet. Int. Soc. Infect. Dis., Rio de Janeiro (Abstr. 473)
94. Ross LA, Kim KS, Mason WH Jr, Gomperts E. 1990. Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am. J. Med. 88:313-14
95. Saint-Marc T, Touraine JL, Berra N. 1992. Beneficial effects of intravenous immunoglobulins in AIDS. Lancet 340:1347 (Lett.)
96. Schrappe-Becher M, Rasokat H, Bauer P, et al. 1990. High-dose intravenous immunoglobulin in HIV-1 infected adults with AIDS-related complex and Walter-Reed. Vox Sang. 59(Suppl.1):3-14
97. Yap PL, Todd AA, Williams PE, et al. 1991. Use of intravenous immunoglobulin in acquired immune deficiency syndrome. Cancer 68:1440-50
98. Karpas A, Hill F, Youle M, et al. 1988. Effects of passive immunization in patients with the acquired immunodeficiency syndrome. Proc. Natl. Acad. Sci. USA 85: 9234-37
99. Jackson GG, Perkins JT, Rubenis M, et al. 1988. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet 2:647-52
100. Vittecoq D, Mattlinger B, Barré-Sinoussi F, et al. 1992. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusion of seronegative plasma. J. Infect. Dis. 165:364-68
101. Levy J, Youvan T, Lee ML, et al. 1994. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. Blood 84:2130-35
102. Duhem C, Dicato MA, Ries F. 1994. Side-effects of intravenous immune globulins. Clin. Exp. Immunol. 97:79-83
103. Lederman HM, Roifman CM, Lavi S, Gelfand EW. 1986. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am. J. Med. 81:443-46
104. Lane RS. 1983. Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet 2:974-75 (Lett.)
105. Lever AM, Brown D, Webster AD, Thomas HC. 1984. Non-A, non-B hepatitis occurring in a gammaglobulinemia patients after intravenous immunoglobulin. Lancet 2: 1062-64
106. Ochs HD, Fischer SH, Virant FS, et al. 1985. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet 1:404-5
107. Webster AD, Lever AM. 1986. Non-A, non-B hepatitis after intravenous immunoglobulin. Lancet 1:323 (Lett.)
108. Bjorkander J, Cunningham-Rundles C, Lundin P, et al. 1986. Intravenous immunoglobulin prophylaxis causing liver damage in 17 of 144 patients with hypogamma globulinemia or IgG subclass deficiency. In Abstr. 2nd Meet Eur. Group Immunodefic., Kerkade, The Netherlands (Abstr. 27)
109. Bjorkander J, Cunningham-Rundles C, Lundin P, et al. 1988. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am. J. Med. 84:107-11
110. Leen CL, Yap PL, Neill G, et al. 1986. Serum ALT levels in patients with primary hypogammaglobulinemia receiving replacement therapy with intravenous immunoglobulin on fresh frozen plasma. Vox. Sang. 50:26-32
111. Williams PE, Yap PL, Gilloon J, et al. 1988. Non-A, non-B hepatitis transmission by intravenous immunoglobulin. Lancet 2:501 (Lett.)
112. Lockner D, Bratt G, Lindborg A, Tornebohm E. 1987. Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon. Acta Med. Scand. 221:413-15